Cetrorelix: profile and news

Aeterna regains global rights to cetrorelix Jan 31, 2006
...and its partner Solvay Pharmaceuticals have reached an agreement whereby Aeterna will regain exclusive global rights to its cetrorelix product, without any ... - Pharmaceutical Business Review

AEterna Zentaris Reports 2005 Fourth Quarter and Full-Year ... Mar 1, 2006
Product Development Pipeline Advancements - Cetrorelix: Initiation of pivotal clinical program in endometriosis by partner, Solvay and Phase 2 trial in benign ... - MSN Money

AEterna Zentaris Reports 2005 Fourth Quarter and Full-Year ... Mar 1, 2006
...to $23.3 million for the same period in 2004 due to the Company's advancements in its product pipeline with a particular effort on cetrorelix, ozarelix, and ... - Black Enterprise,

AEterna Zentaris swings to Q4 profit of US$936K from year-ago $2M ... Mar 1, 2006
..."Over the past year, we made great strides in advancing our lead product development candidates, cetrorelix, ozarelix and perifosine through the pipeline ... - CBC News,

AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for ... Jan 30, 2006
...regains exclusive worldwide (ex-Japan) rights on its lead Luteinizing Hormone Releasing Hormone (LHRH) antagonist product candidate, cetrorelix for the benign ... - Canada NewsWire (press release),

(PRN) - Sanmina-SCI Revises Stock Compensation Expenses and Issues ... Jan 30, 2006
...[+]. (PRN) - AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia ... [+. ... - Bolsamania.com,

AEterna Zentaris appoints former Abbott Vice President to its ... Jan 25, 2006
This will surely be a great asset in the development of our own products, cetrorelix and ozarelix, currently being studied in benign prostatic hyperplasia and ... - Yahoo! News (press release)

AEterna Zentaris to Hold Investor and Analyst Day on November 21 ... Nov 15, 2005
...experts have been invited to speak about the opportunities for products currently under development, with a particular emphasis on cetrorelix, ozarelix (D-63153 ... - Yahoo! News (press release)

AEterna Zentaris Announces Completion of Patient Enrollment for ... Aug 29, 2005
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide®. ... - Yahoo News (press release)

AEterna Zentaris Reports 2005 Second Quarter Financial and ... Aug 3, 2005
...development over the next year, is now considered as another lead product in our promising LHRH antagonist therapeutic approach, along with cetrorelix which is ... - Yahoo News (press release)

AEterna Zentaris Announces 2005 Second Quarter Financial and ... Jul 27, 2005
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R). Cetrorelix is also in late ... - Canada NewsWire (press release)

Women: New Drugs May Protect Fertility From Chemotherapy Jul 13, 2005
...chemotherapy. The drugs, known as D-Trp6-GNRHa and cetrorelix, work by blocking the hormone signals that stimulate the ovaries to function. ... - All Headline News <**results**>

Drug Combo Preserves Fertility in Girls Undergoing Chemo Jun 7, 2005
...girls with a variety of hematologic malignancies, co-administration of a GnRH agonist (D-Trp6-GNRHa) and GnRH-antagonist (cetrorelix) rapidly downregulated the ... - Cancerpage.com,

AEterna Zentaris' Partner Spectrum Granted IND from FDA to Conduct ... May 31, 2005
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide®. ... - Yahoo News (press release)

Drugs preserve fertility of girls receiving chemo Jun 7, 2005
...future. The drugs, known as D-Trp6-GNRHa and cetrorelix, work by blocking the hormone signals that stimulate the ovaries to function. ... - ABC News

COMBINATION OF TWO DRUGS PRESERVES FERTILITY IN YOUNG WOMEN ... Jun 9, 2005
...cancers. The two drugs, known as cetrorelix and D-Trp6-GNRHa, block the hormone signals that stimulate the ovaries to function. ... - Newsinferno.com,

AEterna Zentaris Expands Therapeutic Approaches in Oncology to ... Apr 21, 2005
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R). Cetrorelix is also in late ... - Canada NewsWire

AEterna Zentaris Subsidiary Atrium Biotechnologies Completes ... Apr 6, 2005
For one, cetrorelix, already marketed for in vitro fertilization, is now in its final phase of development with Solvay for endometriosis; an indication which ... - Canada NewsWire,

AEterna Zentaris Reports 2004 Fourth Quarter and Full-Year ... Feb 28, 2005
...of $5.8 million, compared with a net loss of $28.1 million in 2003; - Successful completion of a seven Phase II trial program of cetrorelix in endometriosis ... - Yahoo News (press release)

AEterna Zentaris Reports 2004 Fourth Quarter and Full-Year ... Feb 28, 2005
This increase in operating income is mainly due to non-recurrent milestone payments related to cetrorelix Phase II positive results, the realignment of the ... - ArriveNet (press release),

AEterna Zentaris Subsidiary Atrium Biotechnologies Files ... Feb 17, 2005
The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R), and has successfully ... - Canada NewsWire (press release),

Other information

Indication
For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Pharmacology
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Mechanism Of Action
Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Drug Category
Infertility Agents; Hormone Antagonists; ATC:H01CC02

Brand Names/Synonyms
Cetrorelix; Cetrorelix Acetate; Cetrorelix [Inn]; Cetrorelixum [Inn-Latin]; Cetrotide; Cetyl Pyridinium Bromide; Cetyl Pyridinium Chloride; Cetyl Pyridinium Chloride for Synthesis; Cetylpyridinium Chloride Monohydrate; Chondroitin Hydrochloride; Hexadecyl Pyridinium Bromide; Hexadecylpyridinium Chloride Monohydrate; N-Cetylpyridinium Bromide; N-Hexadecylpyridinium Bromide; Pyrisept; SB-75

Dosage Forms
POWDER FOR SOLUTION

Absorption
Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.

Interactions
-->Interactions for Cetrorelix:

No formal drug interaction studies have been performed with Cetrotide^®.

Chemical IUPAC Name
Not Available

Chemical Formula
Not Available

Half Life
~62.8 hours

Drug Type
Approved Drug

# Accession No
APRD00686

CAS Registry Number
120287-85-6